B+
Bull case
20%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
DRUG
Bright Minds BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The reported Phase 2 seizure reductions and C$307.8 million of June 30, 2026 cash support further development if longer-term data and subsequent trials validate the signal. The company says cash resources cover at least the following twelve months.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
R&D spending increased to C$28.0 million for the nine months ended June 30, 2026, from C$6.3 million a year earlier. Despite substantial cash, management says additional capital may eventually be required and equity issuance could dilute holders. Company MD&A.
Momentum
13
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.00 · Bull $73.00 · Bear $27.00Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $149.11
Why
Momentum13 · Δ7d +1.7
Value41 · Δ7d -0.1
Sentiment41 · Δ7d -1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • R&D spending increased to C$28.0 million for the nine months ended June 30, 2026, from C$6.3 million a year earlier. Despite substantial cash, management says additional capital may eventually be required and equity issuance could dilute holders. Company MD&A.
- • Small, open-label Phase 2 cohorts limit confidence that BMB-101 efficacy will replicate in controlled trials. Company Phase 2 release.
- • The efficacy evidence remains small and open-label; later trials could fail to reproduce it.
Catalyst clock
2026-12-31
Additional BMB-101 outcomes
Lead driver: Value · See fundamentals
Momentum
13
8% active weight
Current posture
7d trendSoftening
Δ7d
+1.7
Δ21d
+5.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
41
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
-8.9
Why this grade
Composite grade F. Momentum 13.3 / Value 40.6 / Sentiment 40.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$517.67M
Beta
-0.59
Shares Out
9.86M
P/E (TTM) · Derived
-41.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-26.47
Rev YoY
-
EPS YoY
-67.0%
Gross Margin
-
Op Margin
-
Net Debt
-$59.5M
Current Ratio
121.97
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data